vendredi 8 septembre 2017

Onco Actu du 8 septembre 2017

2. Etiologie

Cancer, vitamin supplements, and unexpected consequences [Science-Based Medicine]

3.3 Prévention - Vaccins

Anti-HPV vaccine myths have fatal consequences [The Irish Times]

3.7 Alcool

Drinks industry distorts alcohol cancer risk: scientists [Reuters]

Drinks industry downplaying alcohol-cancer link – report [The Guardian]

5. Traitements

Multivitamins May Reduce Incidence of Neuropathy from Chemotherapy [Roswell Park Cancer Institute]

5.1 Traitements - Pré-clinique

Zika virus may be useful in treating brain tumours [NHS Choices]

5.12.1 Immunothérapies - partenariats

GSK exercises option on phase I/II NY-ESO T-cell therapy (GSK3377794) [GSK]

Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug [EndPoints]

Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance [EndPoints]

5.12.3 Immunothérapies-combinaisons

Hammered by critics, NewLink strikes back with positive PhII indoximod data — and shares rocket up [EndPoints]

Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma [NewLink]

CheckMate -214 Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma [BMS]

5.12.4 Immunothérapies - Essais

Celgene Provides Update on the Fusion™ Clinical Program [Celgene]

5.12.5 Immunothérapies - Pharma

GSK bets on pioneering cancer therapy with Adaptimmune deal [Reuters]

5.12.8 Immunothérapies - Economie

Google helps boost Gritstone’s neoantigen R&D gamble to $195M as researchers prep for first human study [EndPoints]

5.2 Pharma

Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer [Kura]

5.2.3 Pharma - économie

Lilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth [Lilly]

Lilly will cut 3,500 jobs, or 8 percent of its global workforce, to revamp [STAT]

Personalized Cancer Vaccine Company Raises $93 Million [Forbes]

Lilly to lay off 8 percent of employees in bid to cut costs [Reuters]

Merck just plowed millions into this start-up to help get drugs to market faster [CNBC]

5.3 Traitements - FDA, EMA, NICE...

FDA’s plan to engage the public in the agency’s new effort to strengthen and modernize FDA’s regulatory framework [FDA Voice]

Following up on Trump’s orders, the FDA wants to know: which regulations and paperwork requirements need to go? [EndPoints]

5.6.13 ESMO - Prostate

ESMO 2017 Press Release: Patients with High Risk Prostate Cancer May Benefit “Equally” From Two New Treatments [ESMO]

5.6.14 ESMO - Ovaire

Clovis Oncology Presents Comprehensive Datased from Successful Phase 3 ARIEL3 Maintenance Treatmeent Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017 [Clovis]

ESMO 2017 Press Release: Rucaparib Boosts Progression-free Survival in BRCA Mutant Recurrent Ovarian Cancer [ESMO]

5.6.16 ESMO - Appareil digestif

ESMO 2017 Press Release: Pembrolizumab: Promising Response Rate in Pretreated Metastatic Gastric Cancer [ESMO]

ESMO 2017 Press Release: New Data Confirms Superiority of Docetaxel Based Triplet Therapy in Gastric Cancer [ESMO]

5.6.2 ESMO - Divers

ESMO 2017 Press Release: DNA Sequencing Could Open Up New Drug Indications for Patients with Rare Cancers [ESMO]

5.6.4 ESMO - Poumon

Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer [BMS]

5.6.6 ESMO - Sein

ESMO 2017 Press Release: LORELEI: Taselisib Boosts Breast Tumor Shrinkage [ESMO]

5.6.7 ESMO - Immunothérapies

Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress [Roche]

ESMO Roundup: Immune Design rolls out its first data on a combo I/O approach with Genentech’s Tecentriq [EndPoints]

Merck's immunotherapy, chemo mix shows extended lung cancer gains [Reuters]

Roche blood test could help 'personalize' cancer immunotherapy [Reuters]

6.10 Politiques

The secret to Germany’s scientific excellence [Nature]

6.11 Patients

Faced with life-threatening diseases, patients take over [San Diego Union Tribune]

6.6 Publications

UCSF, VA investigations find “clear evidence” of misconduct in cancer papers [Retraction Watch]

A Confusion of Journals — What Is PubMed Now? [The Scholarly Kitchen]

6.7 DMP, Big Data & applis

Facebook just held a breakfast to promote its 'clinical trials strategy' to drug marketers [CNBC]

Don't let IBM's blunders in health care blind you to the huge benefits of technology in medicine [CNBC]

6.9 Controverses

Allow Me to Peruse Your Grant [In the Pipeline]

Dr. Vinay Prasad, OHSU's iconoclastic oncologist, calls out shoddy medicine [The Oregonian]